Content about Chairman

NEW YORK — Nielsen Holdings on Monday announced that Rick Kash has been appointed vice chair and will join CEO David Calhoun and vice chair Susan Whiting in the office of the CEO. Nielsen also named Mitchell Habib COO.

BOCA RATON, Fla. — Long-time industry veteran Jonathan Stern, 69, passed last month at his home in Boca Raton, Fla., after a one-year battle with pancreatic cancer. Services were held Nov. 13 at Riverside Memorial Chapel in New York.
 
Stern was credited with building the Keystone Organization into a leading health and beauty sales agency, which merged into Crossmark in 2000. Stern retired two years after the Keystone/Crossmark merger but came out of retirement to serve as an honorary chairman for the Greenwood Group in 2004.
 

BOONTON, N.J. — Unigene Labs, a developer of peptide-based therapeutics, on Wednesday appointed Walgreens' Thomas Sabatino Jr. to its board of directors.

"[Sabatino's] extensive industry experience and impressive track record — specifically, his knowledge of the legal and regulatory landscape for pharmaceutical companies — will be invaluable as Unigene continues to execute against its business transformation," Unigene chairman Richard Levy said.

ST. LOUIS — Ralcorp Holdings announced that Terence Block will serve as president and COO of Post Holdings, effective Jan. 1, 2012. Block also will join the board of directors of Post Holdings following completion of the separation of the Ralcorp and Post cereal business.

NEW YORK — Coty has announced that Bart Becht, former Reckitt Benckiser CEO, has joined its board as nonexecutive chairman.

Becht stepped down as CEO of Reckitt Benckiser, a U.K.-based consumer goods company, in August 2011.

WASHINGTON — The Federal Trade Commission released a report Tuesday finding that drug companies entered 28 deals that the FTC called anticompetitive and said would increase healthcare costs for consumers and the government.

The FTC, which under the leadership of chairman Jon Leibowitz, repeatedly has attacked what it calls "pay-for-delay" deals between branded and generic drug manufacturers and has been lobbying the Congressional Joint Select Committee on Deficit Reduction, also known as the super committee, to ban the deals.

CHEVY CHASE, Md. — Patients with diabetes may benefit from a system that provides continuous, real-time glucose readings, according to new clinical practice guidelines released by the Endocrine Society.

While most patients with diabetes measure blood glucose by pricking their skin to get a drop of blood and then measuring it with a glucose meter, continuous glucose monitoring measures glucose in the interstitial fluid, the fluid between cells just under the skin.

SUNBURY, Pa. — Weis Markets on Wednesday reported third-quarter sales of $678.6 million, an increase of 6%. Comparable-store sales increased 6.5% during the thirteen-week period ended Sept. 24.

"Our company continues to generate strong results in a difficult economic environment," stated Robert Weis, Weis Markets' chairman. "Cautious consumer spending due to the poor economy continues to impact our business, [and] fuel and wholesale inflation impacted our business during the period."

PITTSBURGH — Mylan co-founder and former chairman and CEO Milan "Mike" Puskar died Saturday, the generic drug maker said. Puskar, who retired from Mylan as chairman in 2009, was 77.

ARLINGTON, Va. — The chairman of the House of Representatives' Committee on Education and the Workforce has introduced legislation that is designed to prevent the National Labor Relations Board from implementing sweeping changes to the workplace.

Jon Kline on Wednesday itnroduced H.R. 3094, the Workforce Democracy and Fairness Act, will force the NLRB to change course and reaffirm the protections workers and employers have received for decades, the House committee said.

HAWTHORNE, N.Y. — Taro Pharmaceutical Industries recently appointed a new member to its board, following the resignation of Hasmukh Shah.

Shah, who cited personal reasons for leaving the drug maker's board, was replaced by Dov Pekelman, who currently serves as chairman of both Atera Networks and Gilon Investments. Pekelman also served as senior consultant for Teva Pharmaceutical Industries from 1985 to 2008.

Pekelman will serve until Taro's next annual general meeting of shareholders.

The issue of patent settlements, their effect on drug prices and availability, and by extension their legality has been around for a long time and will likely remain an issue for years to come. But according to a report released in May by the Federal Trade Commission, the settlements have been on the rise, increasing from 16 in 2009 to 31 in 2010.